UBS analyst Xian Deng maintained a Buy rating on Ipsen (0MH6 – Research Report) today and set a price target of €145.00. The company’s shares ...

Ipsen SA (IPSEF) reports robust financial performance with a 9.9% sales increase and strategic pipeline developments, despite ...

Ipsen expects total sales growth of more than 5% at constant exchange rates in 2025, supported by the continued expansion of products like IQIRVO, ONIVYDE, and Bylvay. However, Somatuline faces ...

Shares of Ipsen (EPA:IPN) dropped 2.7% as the market reacted to the company's mixed fourth-quarter results. Despite reporting ...

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% ...

In a report released on February 11, Justine Telliez from Kepler Capital maintained a Hold rating on Ipsen (0MH6 – Research Report), with a ...

Morgan Stanley (NYSE:MS) analysts adjusted their stance on Ipsen SA (EPA:IPN:FP) (OTC: IPSEF), downgrading the stock from Equalweight to Underweight. The firm also set a new price target of EUR120.00 ...

A former executive at French drugmaker Ipsen was sentenced on Thursday to two months in a U.S. prison for illegally trading ...

Infant mortality in the U.S. has increased by 7% since the 2022 Dobbs v. Jackson U.S. Supreme Court decision overturned the ...

The Royalty Financing Bonds issued by GENFIT will not bear interest. Instead, the returns on these bonds will be tied to a portion of the royalties GENFIT receives under the Ipsen agreement from ...

BOSTON (Reuters) -A former executive at French drugmaker Ipsen was sentenced on Thursday to two months in a U.S. prison for illegally trading on inside information he learned about his company's plans ...